Tamoxifen, 17beta-oestradiol and the calmodulin antagonist J8 inhibit human melanoma cell invasion through fibronectin.
Invasion through stromal extracellular matrix (ECM) is part of the complex, multistep process of tumour cell invasion and metastasis. Our group has previously demonstrated that calcium and calmodulin are important in another step in the metastatic cascade - that of attachment of cells to ECM. Interestingly, the non-steroidal anti-oestrogen tamoxifen (which also has calmodulin antagonist activity), used in the treatment of breast cancer and now in metastatic cutaneous melanoma, can inhibit the attachment of normal and neoplastic cells to ECM. In this study, we investigated whether such drugs, known to inhibit cell attachment, could also subsequently reduce their invasion through a layer of human fibronectin. We examined the ability of the specific calmodulin antagonist J8, tamoxifen and its two major metabolites, N-desmethyltamoxifen (N-des) and 4-hydroxytamoxifen (4-OH), as well as the pure anti-oestrogen ICI 182,780 and 17beta-oestradiol to inhibit invasion of the human cutaneous melanoma cell line, A375-SM, uveal melanoma cells and uveal melanocytes. A375-SM cells and uveal melanoma cells showed a high level of invasion (15.2% and 33.7% respectively) compared with melanocytes (around 5%) under the experimental conditions used. Submicromolar concentrations of N-des, tamoxifen, J8 and 17beta-oestradiol significantly reduced the invasiveness of the A375-SM cell line. The uveal melanoma cells also showed similar inhibition, although at higher concentrations of these agents. 4-OH and ICI 182, 780 had little or no effect on invasion of A375-SM cells (these were not tested on uveal melanoma cells). All cells used in this study were found to be negative for type I nuclear oestrogen receptors, reinforcing the possibility that tamoxifen and 17beta-oestradiol can act via mechanisms unrelated to binding to classical oestrogen receptors to inhibit tumour cell invasion.
Dewhurst
L O
LO
Department of Medicine, University of Sheffield, UK.
Gee
J W
JW
Rennie
I G
IG
MacNeil
S
S
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D004354:Drug Screening Assays, Antitumor; D004958:Estradiol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology*; D005353:Fibronectins; D000077267:Fulvestrant; D006801:Humans; D008545:Melanoma / Q000737:chemistry / Q000188:drug therapy / Q000473:pathology* / Q000556:secondary; D009281:Naphthalenes / Q000008:administration & dosage / Q000494:pharmacology*; D009361:Neoplasm Invasiveness / Q000517:prevention & control*; D011980:Receptors, Progesterone / Q000032:analysis; D012878:Skin Neoplasms / Q000737:chemistry / Q000188:drug therapy / Q000473:pathology*; D013449:Sulfonamides / Q000008:administration & dosage / Q000494:pharmacology*; D013629:Tamoxifen / Q000008:administration & dosage / Q000494:pharmacology*; D014604:Uveal Neoplasms / Q000737:chemistry / Q000188:drug therapy / Q000473:pathology*
D000970:Antineoplastic Agents; D005353:Fibronectins; D009281:Naphthalenes; D011980:Receptors, Progesterone; D013449:Sulfonamides; D013629:Tamoxifen; C077098:N-(8-aminooctyl)-5-iodonaphthalene-1-sulfonamide; D000077267:Fulvestrant; D004958:Estradiol